Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 21 Parkinson Disease 4, Autosomal Dominant Lewy Body 15 Carcinoma, Renal Cell 7 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Differentiated Thyroid Cancer (DTC) 1 Colorectal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Advanced Malignancies 1 Advanced Endometrial Cancer 1

Interventions

Interferon-alpha 7 aldesleukin 6 Sunitinib 6 Radiotherapy 5 Nivolumab 5 Doxorubicin 5 Vincristine 4 Ipilimumab 4 Filgrastim 4 Dactinomycin 4 Chemotherapy, Adjuvant 4 Axitinib 4 cabozantinib 3 Sorafenib 3 Everolimus 3 Etoposide 3 Cyclophosphamide 3 temsirolimus 2 pembrolizumab 2 Ifosfamide 2 G250 monoclonal antibody 2 Fluorouracil 2 Carboplatin 2 Bevacizumab 2 vitespin 1 shark cartilage extract 1 pazopanib 1 lenvatinib 1 glutamic acid diethyl ester 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Kidney Neoplasms × lenvatinib × Clear all

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡